biotech · Duchenne Muscular Dystrophy · Duchenne muscular dystrophy · SLDB
Solid Biosciences
Solid Biosciences is a biotech organization headquartered in Boston, USA. It trades on NYSE under ticker SLDB. Primary therapeutic focus areas include Duchenne Muscular Dystrophy, Duchenne muscular dystrophy, Glioblastom
500 Rutherford Ave, Third Floor, Boston, Massachusetts 02129, US HQ
2013 Founded
155 Employees
Public company Type
SLDB · NYSE Ticker
Company details
- Status
- Public
- HQ
- 500 Rutherford Ave, Third Floor, Boston, Massachusetts 02129, US
- Founded
- 2013
- Employees
- 155
- Programs
- 16
- Drugs
- 20
- Patents
- 2
genexolPM + cisplatin
Phase 2 · small molecule · Locally Advanced Head and Neck Squamous Cell Carcinoma
genexolPM + cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma is a Phase 2 program (small_molecule) at Solid Biosciences with 1 ClinicalTrials.gov record(s).
Internal code CRCST-L-0007
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Solid Biosciences
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Status
- completed
- Trials
- 1